Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.07
Nov 19 • 3:59 PM ET Dollar change-0.01 Percentage change(-0.93%)
Aftermarket Close
1.07
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
33.65M
Enterprise Value
6.13M
Income
10.60M
Sales
35.00M
Book/sh
0.78
Cash/sh
0.91
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
25
IPO
Jun 02, 2011
P/E
3.19
Forward P/E
-
PEG
-
P/S
0.96
P/B
1.37
P/C
1.17
P/FCF
-
EV/EBITDA
0.60
EV/Sales
0.18
Quick Ratio
4.00
Current Ratio
4.00
Debt/Eq
0.05
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
0.34
EPS next Y
-0.66
EPS next Q
-0.21
EPS this Y
121.71%
EPS next Y
-379.93%
EPS next 5Y
16.05%
EPS past 3/5Y
7.39% 9.91%
Sales past 3/5Y
-54.09% -
EPS Y/Y TTM
130.26%
Sales Y/Y TTM
38788.89%
EPS Q/Q
-12.95%
Sales Q/Q
-100.00%
Insider Own
1.76%
Insider Trans
0.00%
Inst Own
16.08%
Inst Trans
-2.23%
ROA
23.91%
ROE
55.23%
ROIC
42.22%
Gross Margin
96.93%
Oper. Margin
26.07%
Profit Margin
30.27%
SMA20
-25.23%
SMA50
-16.90%
SMA200
-5.43%
Trades
Shs Outstand
31.44M
Shs Float
30.89M
52W High
1.72 -37.79%
52W Low
0.74 45.56%
Volatility
15.17% 11.31%
ATR (14)
0.14
RSI (14)
36.13
Beta
0.35
Rel Volume
0.87
Avg Volume
191.24K
Volume
166,516
Perf Week
-32.70%
Perf Month
-22.46%
Perf Quarter
-2.73%
Perf Half Y
-9.32%
Perf YTD
-21.32%
Perf Year
-21.32%
Perf 3Y
-76.17%
Perf 5Y
-85.96%
Perf 10Y
-96.67%
Prev Close
1.08
Price
1.07
Change %
-0.93%
Consensus
Strong Buy
Avg. Price Target
$4.50
Implied Upside
+320.6%
Analysts13incl. previous ratings
Rating Distribution11 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 07, 2024Downgrade
RILY logoRB. Riley Securities
Buy → Neutral$16 → $2+86.9%
May 14, 2024Initiated
SStephens
Overweight$25+2,236.4%
Sep 06, 2023Initiated
HSBC logoHHSBC Securities
Buy$11.60+984.1%
Feb 21, 2023Downgrade
WWilliam Blair
Outperform → Mkt Perform
Sep 08, 2022Initiated
CCantor Fitzgerald
Overweight$20+1,769.2%
Aug 25, 2022Initiated
RILY logoRB. Riley Securities
Buy$16+1,395.3%
Nov 05, 2020Initiated
AAlliance Global Partners
Buy$25+2,236.4%
Dec 06, 2017Initiated
BB. Riley FBR, Inc.
Buy$2.75+157.0%
Oct 23, 2017Resumed
RROTH Capital
Buy$6+460.7%
Sep 14, 2017Initiated
MMaxim Group
Buy$3+180.4%
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, discovery, and clinical development of targeted radiotherapies. It also develops and markets medicines for relapsed and refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
M.S.Mr. Sandesh C. Seth M.B.A.
CFO & Principal Financial OfficerDr. Matthew T. David M.D.
Chief Scientific OfficerDr. Adeela Kamal Ph.D.
Ph.D.Dr. Paul Diamond Esq.
Chief Business OfficerMs. Lynn M. Bodarky M.B.A.